度普利尤单抗治疗IgG4相关疾病:病例系列与文献综述
本文报道了本机构连续4例符合2019年ACR/EULAR分类标准的IgG4相关疾病(IgG4-RD)合并重度哮喘和慢性鼻窦炎伴鼻息肉患者接受度普利尤单抗(DUP)治疗的疗效,并结合既往文献进行综述。2例未用全身糖皮质激素者在6个月内肿胀下颌下腺体积缩小约70%;2例使用糖皮质激素者6个月内日剂量分别减少10%和50%;全部4例血清IgG4浓度和IgG4-RD应答指数在6个月内下降。
要点
- 4例IgG4-RD合并重度哮喘和慢性鼻窦炎伴鼻息肉患者接受度普利尤单抗治疗。
- 2例未用全身糖皮质激素者6个月内肿胀下颌下腺体积缩小约70%。
- 全部4例6个月内血清IgG4浓度和IgG4-RD应答指数下降。
核心结论
- 度普利尤单抗在6个月内可缩小IgG4-RD患者肿胀的下颌下腺体积、降低血清IgG4水平、降低应答指数并减少糖皮质激素日剂量。
- 作者认为度普利尤单抗可改善IgG4-RD疾病活动度,并可作为IgG4-RD患者的保激素药物。
研究设计与样本
- 本机构连续4例IgG4-RD患者的病例系列,并结合既往文献进行综述。
- 全部患者接受度普利尤单抗治疗,均符合2019年ACR/EULAR的IgG4-RD分类标准,并合并重度哮喘和慢性鼻窦炎伴鼻息肉。
主要发现
- 2例未用全身糖皮质激素者,6个月内肿胀下颌下腺体积缩小约70%。
- 2例使用糖皮质激素者,6个月内糖皮质激素日剂量分别减少10%和50%。
- 全部4例在6个月内血清IgG4浓度和IgG4-RD应答指数下降。
临床怎么用
- 作者认为度普利尤单抗可改善IgG4-RD疾病活动度,并可作为IgG4-RD患者的保激素药物。
局限性
- 原文指出,由于病例报告有限且结局存在争议,度普利尤单抗对IgG4-RD的疗效尚在讨论中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Dupilumab (DUP) is a monoclonal antibody that acts on the interleukin (IL)-4 receptor alpha, which inhibits IL-4 and IL-13 signalling and is approved for type 2 inflammatory diseases such as asthma, chronic rhinosinusitis with nasal polyposis and atopic dermatitis; however, the efficacy of DUP to IgG4-related disease (IgG4-RD) is under discussion due to the controversial outcomes based on the several case reports. Here, we reviewed the efficacy of DUP in four consecutive patients with IgG4-RD in our institute and the previous literature.All patients administered DUP fulfilled the 2019 ACR/EULAR classification criteria for IgG4-RD complicated with severe asthma and chronic rhinosinusitis with nasal polyposis. Two cases were administered DUP without systemic glucocorticoids (GCs), and in 6 months, the volume of swollen submandibular glands (SMGs) was reduced by approximately 70%. Two cases receiving GCs successfully reduced their daily dose of GCs (10 and 50% reduction, respectively) with dupilumab in 6 months. In all four cases, serum IgG4 concentration and IgG4-RD responder index decreased in 6 months.DUP reduced the volume of the swollen SMGs, serum IgG4 levels, responder index and the daily dose of GCs in patients with IgG4-RD with severe asthma or eosinophilic rhinosinusitis in 6 months.The efficacy of DUP to IgG4-RD is under discussion due to the limited case reports with controversial outcomes. Here, we demonstrated that two patients with IgG4-RD treated by DUP without systemic GCs, showed volume reduction of swollen SMGs and two cases showed GC-sparing effects by DUP. DUP can ameliorate the disease activity and be a steroid-sparing agent in patients with IgG4-RD.
引用
- Kanda M, Kamekura R, Sugawara M, et al. IgG4-related disease administered dupilumab: case series and review of the literature. RMD Open. 2023. PMID: 36894196. doi:10.1136/rmdopen-2023-003026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。